Research & Development
Pioneering scientific innovation to discover and develop breakthrough treatments that address unmet medical needs.
Innovation at the Core
Our research and development strategy focuses on translating cutting-edge science into transformative medicines. With an annual R&D investment exceeding $500 million, we are committed to pushing the boundaries of pharmaceutical innovation.
Therapeutic Focus Areas
We concentrate our research efforts in therapeutic areas where we can make the greatest impact on patient lives.
Cardiovascular
Developing next-generation treatments for heart failure, hypertension, and atherosclerosis.
Neuroscience
Advancing therapies for neurodegenerative diseases, depression, and anxiety disorders.
Oncology
Pioneering precision medicine approaches for various types of cancer.
Immunology
Creating innovative treatments for autoimmune diseases and transplant rejection.
Our Pipeline
A robust pipeline of innovative candidates across various stages of development.
Our Capabilities
World-class scientific expertise and cutting-edge technologies driving our research.
Drug Discovery
State-of-the-art screening platforms and AI-driven compound identification.
Formulation Science
Advanced drug delivery systems for improved efficacy and patient compliance.
Biomarker Development
Precision diagnostics for targeted treatment selection and monitoring.
Clinical Development
Global clinical trial capabilities across multiple therapeutic areas.
Active Clinical Trials
Explore our ongoing clinical studies and learn how you can participate.
CardioVex Plus Phase III
Cardiovascular • Phase III • Global (150 sites)
NeuroCalm Extension Study
Neuroscience • Phase II • North America, Europe
OncoTreat Combination
Oncology • Phase I • United States
Stay Updated with Our Latest News
Subscribe to our newsletter for the latest pharmaceutical insights, research updates, and company news.